Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies.
Xiang GaoToshimitsu FujiiByong Duk YeJen-Wei ChouKen SugimotoQian CaoKristina KligysKaoru MurakoshiDennis TengYafei ZhangHiroshi NakasePublished in: Journal of gastroenterology and hepatology (2023)
Consistent with non-Asian and global population results, risankizumab was effective and well tolerated in Asian patients with Crohn's disease.